EQUITY RESEARCH MEMO

Zanteris

Generated 5/11/2026

Executive Summary

Conviction (model self-assessment)20/100

Zanteris is a private French company founded in 2016, specializing in clinical project and vendor management services for the pharmaceutical industry, with a focus on oncology and drug discovery. Based in Paris, the company positions itself as a 'go-to expert' for seamless coordination and successful execution of clinical projects. However, the public information is limited; no pipeline, funding, or stage details are available. The description suggests a service-oriented model rather than a drug developer, which may limit its upside as a traditional biotech investment. Without disclosed assets or partnerships, Zanteris appears to be an early-stage service provider with an unclear competitive advantage.

Locked sections
  • · Pipeline Analysis
  • · Competitive Landscape
  • · Catalyst Calendar (full 12-month)
  • · Bull Case
  • · Bear Case
  • · Counterfactual Scenarios
  • · Valuation Notes
  • · SEC Filing Highlights
  • · Insider Activity
  • · Literature Watch
  • · Patent Landscape
  • · Mechanism Cluster Map
  • · Audio Briefing (5 min)